© Foto: Georgios Kefalas/KEYSTONE/dpa
© 2024 wallstreetONLINE
© Foto: Georgios Kefalas/KEYSTONE/dpa
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
17:10 | In defense of radioligand therapies, Novartis fired off patent lawsuits against Lilly and other rivals | ||
10:30 | Eli Lilly setzt UNGLAUBLICHES Kursziel: Könnte der Kurs JETZT komplett drehen - Experten empfehlen zu handeln! | ||
So | King Faisal Specialist Hospital & Research Centre: KFSHRC & Lilly Collaborate in Alzheimer's Early Detection | RIYADH, Saudi Arabia, Nov. 03, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) and Eli Lilly Saudi Arabia signed an MoU today to improve Alzheimer's patient... ► Artikel lesen | |
So | Eli Lilly and Company Aktie: Solide Ergebnisse erfreuen! | ||
Fr | Pharma Stock Roundup: MRK, PFE, ABBV, NVS, LLY's Q3 Earnings in Focus |
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
19:42 | Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug | ||
18:46 | Novo inks Ascendis deal to develop long-acting GLP-1, other metabolic drugs | ||
15:26 | Novo pens $285M biobucks deal to use Ascendis' tech to create monthly GLP-1 agonist | ||
14:34 | Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock? | ||
14:33 | Gewicht um bis zu einem Viertel reduzieren - Novo Nordisk zündet Innovationsbombe mit neuer Adipositas-Kombinationstherapie |
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
10:17 | Roche und Novartis bleiben von möglichem Trump-Sieg unbeeindruckt | ||
Fr | UCB's tau drug flunks phase 2 Alzheimer's trial days after Roche's exit from $120M bet | ||
Do | Roche weighs whether speedy approval path is open for latest Alzheimer's drug | ||
Do | Roche collects more data to support blood tests for diagnosing Alzheimer's disease | ||
Do | Regeneron's Eylea HD makes progress but doesn't dent the momentum of Roche's Vabysmo |
Unternehmen / Aktien | Kurs | % |
---|---|---|
ELI LILLY AND COMPANY | 741,40 | -1,87 % |
NOVO NORDISK A/S | 101,10 | -2,07 % |
ROCHE HOLDING AG GS | 289,65 | -0,12 % |